Pilot Payer-Provider CollaborationsVideo Categories: Payer-Provider
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1â€“negative melanoma patients seem to respond to antiâ€“PD-1 therapy, although some studies suggest PD-L1â€“negative patients may be better candidates for combination immunotherapy.
Challenges with Oral Oncolytics for Healthcare Practitioners
As more oral oncolytics are developed, choosing the right regimen for prolonged disease-free survival presents a major patient management challenge. Dixie-Lee Esseltine, MD and George Mulligan, PhD explain that healthcare practitioners will have to make informed choices by balancing information emerging across similar trials.